211 related articles for article (PubMed ID: 34210752)
1. AP-2α-Mediated Activation of E2F and EZH2 Drives Melanoma Metastasis.
White JR; Thompson DT; Koch KE; Kiriazov BS; Beck AC; van der Heide DM; Grimm BG; Kulak MV; Weigel RJ
Cancer Res; 2021 Sep; 81(17):4455-4470. PubMed ID: 34210752
[TBL] [Abstract][Full Text] [Related]
2. The EZH2 inhibitor tazemetostat upregulates the expression of CCL17/TARC in B-cell lymphoma and enhances T-cell recruitment.
Yuan H; Nishikori M; Otsuka Y; Arima H; Kitawaki T; Takaori-Kondo A
Cancer Sci; 2021 Nov; 112(11):4604-4616. PubMed ID: 34449935
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of an EZH2 inhibitor in patient-derived orthotopic xenograft models of pediatric brain tumors alone and in combination with chemo- and radiation therapies.
Qi L; Lindsay H; Kogiso M; Du Y; Braun FK; Zhang H; Guo L; Zhao S; Injac SG; Baxter PA; Su JM; Xiao S; Erickson SW; Earley EJ; Teicher B; Smith MA; Li XN
Lab Invest; 2022 Feb; 102(2):185-193. PubMed ID: 34802040
[TBL] [Abstract][Full Text] [Related]
4. Chromatin remodeling by the histone methyltransferase EZH2 drives lung pre-malignancy and is a target for cancer prevention.
Tellez CS; Picchi MA; Juri D; Do K; Desai DH; Amin SG; Hutt JA; Filipczak PT; Belinsky SA
Clin Epigenetics; 2021 Feb; 13(1):44. PubMed ID: 33632299
[TBL] [Abstract][Full Text] [Related]
5. AP-2α Regulates S-Phase and Is a Marker for Sensitivity to PI3K Inhibitor Buparlisib in Colon Cancer.
Beck AC; Cho E; White JR; Paemka L; Li T; Gu VW; Thompson DT; Koch KE; Franke C; Gosse M; Wu VT; Landers SR; Pamatmat AJ; Kulak MV; Weigel RJ
Mol Cancer Res; 2021 Jul; 19(7):1156-1167. PubMed ID: 33753551
[TBL] [Abstract][Full Text] [Related]
6. CREB inhibits AP-2alpha expression to regulate the malignant phenotype of melanoma.
Melnikova VO; Dobroff AS; Zigler M; Villares GJ; Braeuer RR; Wang H; Huang L; Bar-Eli M
PLoS One; 2010 Aug; 5(8):e12452. PubMed ID: 20805990
[TBL] [Abstract][Full Text] [Related]
7. EZH2-mediated inhibition of KLF14 expression promotes HSCs activation and liver fibrosis by downregulating PPARγ.
Du Z; Liu M; Wang Z; Lin Z; Feng Y; Tian D; Xia L
Cell Prolif; 2021 Jul; 54(7):e13072. PubMed ID: 34031939
[TBL] [Abstract][Full Text] [Related]
8. EZH2-Mediated Primary Cilium Deconstruction Drives Metastatic Melanoma Formation.
Zingg D; Debbache J; Peña-Hernández R; Antunes AT; Schaefer SM; Cheng PF; Zimmerli D; Haeusel J; Calçada RR; Tuncer E; Zhang Y; Bossart R; Wong KK; Basler K; Dummer R; Santoro R; Levesque MP; Sommer L
Cancer Cell; 2018 Jul; 34(1):69-84.e14. PubMed ID: 30008323
[TBL] [Abstract][Full Text] [Related]
9. Synergistic silencing by promoter methylation and reduced AP-2α transactivation of the proapoptotic HRK gene confers apoptosis resistance and enhanced tumor growth.
Xu M; Chen X; Chen N; Nie L; Li X; Li Q; Zeng H; Zhou Q
Am J Pathol; 2013 Jan; 182(1):84-95. PubMed ID: 23159945
[TBL] [Abstract][Full Text] [Related]
10. HO-1 promotes resistance to an EZH2 inhibitor through the pRB-E2F pathway: correlation with the progression of myelodysplastic syndrome into acute myeloid leukemia.
He Z; Zhang S; Ma D; Fang Q; Yang L; Shen S; Chen Y; Ren L; Wang J
J Transl Med; 2019 Nov; 17(1):366. PubMed ID: 31711520
[TBL] [Abstract][Full Text] [Related]
11. Failure in post-transcriptional processing is a possible inactivation mechanism of AP-2alpha in cutaneous melanoma.
Karjalainen JM; Kellokoski JK; Mannermaa AJ; Kujala HE; Moisio KI; Mitchell PJ; Eskelinen MJ; Alhava EM; Kosma VM
Br J Cancer; 2000 Jun; 82(12):2015-21. PubMed ID: 10864211
[TBL] [Abstract][Full Text] [Related]
12. The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors.
Zingg D; Debbache J; Schaefer SM; Tuncer E; Frommel SC; Cheng P; Arenas-Ramirez N; Haeusel J; Zhang Y; Bonalli M; McCabe MT; Creasy CL; Levesque MP; Boyman O; Santoro R; Shakhova O; Dummer R; Sommer L
Nat Commun; 2015 Jan; 6():6051. PubMed ID: 25609585
[TBL] [Abstract][Full Text] [Related]
13. EZH2 inhibition confers PIK3CA-driven lung tumors enhanced sensitivity to PI3K inhibition.
Chen F; Liu J; Song X; DuCote TJ; Byrd AL; Wang C; Brainson CF
Cancer Lett; 2022 Jan; 524():151-160. PubMed ID: 34655667
[TBL] [Abstract][Full Text] [Related]
14. Synergistic Anti-Tumor Activity of EZH2 Inhibitors and Glucocorticoid Receptor Agonists in Models of Germinal Center Non-Hodgkin Lymphomas.
Knutson SK; Warholic NM; Johnston LD; Klaus CR; Wigle TJ; Iwanowicz D; Littlefield BA; Porter-Scott M; Smith JJ; Moyer MP; Copeland RA; Pollock RM; Kuntz KW; Raimondi A; Keilhack H
PLoS One; 2014; 9(12):e111840. PubMed ID: 25493630
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of EZH2 in conjunctival melanoma offers a new therapeutic target.
Cao J; Pontes KC; Heijkants RC; Brouwer NJ; Groenewoud A; Jordanova ES; Marinkovic M; van Duinen S; Teunisse AF; Verdijk RM; Snaar-Jagalska E; Jochemsen AG; Jager MJ
J Pathol; 2018 Aug; 245(4):433-444. PubMed ID: 29732557
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of EZH2 enhances the therapeutic effect of 5-FU via PUMA upregulation in colorectal cancer.
Tan X; Zhang Z; Liu P; Yao H; Shen L; Tong JS
Cell Death Dis; 2020 Dec; 11(12):1061. PubMed ID: 33311453
[TBL] [Abstract][Full Text] [Related]
17. Targeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020).
Dockerill M; Gregson C; O' Donovan DH
Expert Opin Ther Pat; 2021 Feb; 31(2):119-135. PubMed ID: 33103538
[TBL] [Abstract][Full Text] [Related]
18. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
19. Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer.
Song X; Gao T; Wang N; Feng Q; You X; Ye T; Lei Q; Zhu Y; Xiong M; Xia Y; Yang F; Shi Y; Wei Y; Zhang L; Yu L
Sci Rep; 2016 Feb; 6():20864. PubMed ID: 26868841
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of the Histone Methyltransferase EZH2 Enhances Protumor Monocyte Recruitment in Human Mesothelioma Spheroids.
Mola S; Pinton G; Erreni M; Corazzari M; De Andrea M; Grolla AA; Martini V; Moro L; Porta C
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
